APIS SARS-CoV-2 IgG ELISA Kit
The APIS SARS-CoV-2 IgG ELISA Kit is intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum (obtained by venous or capillary puncture) run manually.
APIS SARS-CoV-2 IgG ELISA Kit
SARS-CoV-2 IgG levels are reported according to NIBSC working reagent
The kit contains one 96 well microplate coated with SARS-CoV-2 spike protein, sufficient HRP labelled antibody to human IgG and other reagents to perform the indirect ELISA. A maximum of 88 individual samples can be tested on each plate.
Automated results calling using validated APIS analysis template
The APIS SARS-CoV-2 IgG ELISA Kit is an in vitro enzyme-linked immunoassay (ELISA) intended for the quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum (obtained by venous or capillary puncture).
There is an ongoing need for the quantification of antibodies to SARS-CoV-2 to evaluate the immunity status of patients following infection and vaccination.
Results from this assay will aid in clinical decision making, vaccine development and booster dosing, disease prevention and research studies.
Background and ongoing need
The coronavirus SARS-CoV-2 that causes the disease stage COVID-19, emerged in December 2019 there have been over 600 million confirmed cases people and over 6.5 million deaths globally¹. The first patients developed symptoms on December 1, 2019 after which rapid human-to-human transmission and intercontinental spread later ensued, being declared a pandemic by the WHO in March 2020². All ages of the population are susceptible to SARS-CoV-2 infection. Co-morbidities increase the possibility of developing severe respiratory disease that requires hospitalization and can be fatal³.
SARS-CoV-2 IgG ELISA - The APIS Solution
This new innovative assay addresses the unmet needs in current practice;
Delivers highly repeatable and reproducible results for the same patient sample, tested in different laboratories
Quantitative detection of IgG antibodies to SARS-CoV-2 spike protein in human serum
Up to 88 individual samples can be tested per plate
Automated results calling using validated APIS analysis template
SARS-CoV-2 - Unmet Needs
In a time when a high percentage of a population requires multiple doses of a vaccine, limited vaccine doses pose a health risk to the population.
Stratifying people’s susceptibility to infection by determining the level of serum antibodies allows those limited vaccine doses to go to those individuals that are most at risk.